Text Size

Activation of Alternative Cellular Energy (ACE) Pathway in the Therapy of Herpes Virus Infections

This study has been completed.
Sponsor:
Information provided by:
Institute of Progressive Medicine
ClinicalTrials.gov Identifier:
NCT00642785
First received: March 19, 2008
Last updated: May 30, 2008
Last verified: May 2008
History of Changes
  Purpose

The research question to be addressed is whether indirect phototherapy based activation of the body's alternative cellular energy (ACE) pathway will lead to expedited healing of active herpes simplex virus (HSV) and herpes zoster virus (HZV)skin lesions, and also possibly inhibit both latent HSV infections and residual HZV infections.


Condition
Herpes Simplex
Herpes Zoster

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Research Study Examining the Effectiveness of Distant Activation of ACE Pigments Associated With Recurrent Human Herpes Simplex Virus-Induced Skin Lesions.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Institute of Progressive Medicine:

Primary Outcome Measures:
  • Expedited healing of active lesions [ Time Frame: Within 1 day following therapy ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Recurrence of lesions and/or symptoms [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 500
Study Start Date: January 2008
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients with active oral or genital HSV skin lesions
2
Patients with a history of recurrent oral or genital HSV but without an active lesion at the time of treatment
3
Patients with active shingles/zoster
4
Patients with post herpetic neuralgia

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

HSV and HZV infected patients

Criteria

Inclusion Criteria:

  • Clinical diagnosis of active, latent or residual HSV or HZV infection

Exclusion Criteria:

  • Unwilling or unable to provide Informed Consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00642785

Sponsors and Collaborators
Institute of Progressive Medicine
Investigators
Principal Investigator: W John Martin, MD, PhD Institute of Progressive Medicine
  More Information

Publications:

Responsible Party: W. John Martin, Medical Director, Institute of Progressive Medicine
ClinicalTrials.gov Identifier: NCT00642785     History of Changes
Other Study ID Numbers: 071/081
Study First Received: March 19, 2008
Last Updated: May 30, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Institute of Progressive Medicine:
herpes
HSV
zoster
HZV
shingles

Additional relevant MeSH terms:
Herpes Simplex
Herpes Zoster
Herpesviridae Infections
DNA Virus Infections
 Virus Diseases
Skin Diseases, Viral
Skin Diseases, Infectious
Skin Diseases

ClinicalTrials.gov processed this record on May 23, 2013